April 10, 2004 |
Drug maker AaiPharma Inc. said that it had received subpoenas from a federal grand jury for testimony and a variety of documents and that it had been notified that it might soon receive a subpoena from the Securities and Exchange Commission. The company has said it is investigating "sales abnormalities" involving its asthma drug and painkillers. Its chief executive has resigned, and it has received a Nasdaq delisting notice. AaiPharma said it would cooperate with the investigations.